Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) was the target of a large increase in short interest in July. As of July 15th, there was short interest totalling 59,900 shares, an increase of 215.3% from the June 30th total of 19,000 shares. Based on an average trading volume of 1,380,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 10.7% of the company’s shares are short sold.
Salarius Pharmaceuticals Stock Performance
Shares of NASDAQ:SLRX traded up $1.36 during mid-day trading on Thursday, hitting $3.50. The stock had a trading volume of 31,266,346 shares, compared to its average volume of 858,647. The company has a market cap of $2.10 million, a PE ratio of -0.15 and a beta of 0.92. Salarius Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $7.92. The company’s 50 day moving average is $2.94 and its 200-day moving average is $3.92.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($3.28) EPS for the quarter, beating the consensus estimate of ($53.60) by $50.32. On average, equities research analysts predict that Salarius Pharmaceuticals will post -214.4 EPS for the current fiscal year.
Salarius Pharmaceuticals Company Profile
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Further Reading
- Five stocks we like better than Salarius Pharmaceuticals
- Compound Interest and Why It Matters When Investing
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- There Are Different Types of Stock To Invest In
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.